This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pacira Pharmaceuticals Inc (PCRX)

NASDAQ: Health Care

Company Cash Flow
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Cash Flow From Operating Activities
Net Income (Loss) 1.86M -13.72M -63.91M -52.28M
Operating Gains/Losses 58.00K 158.00K 3.43M 1.06M
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -3.49M -7.78M -10.24M -2.24M
(Increase) Decrease in Inventories -32.38M -13.71M -3.48M -10.83M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 9.94M 14.25M 10.24M 1.39M
(Decrease) Increase In Other Current Liabilities -276.00K 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital 5.87M 8.22M 31.00K -18.18M
Other Non-Cash Items 33.37M 24.82M 11.51M 4.78M
Net Cash From Continuing Operations 29.00M 25.47M -43.22M -70.13M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 29.00M 25.47M -43.22M -70.13M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 1.00K
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 80.29M 85.56M 53.12M
Purchases of Property, Plant & Equipment -41.27M -21.89M -12.79M -18.26M
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments 0.00 -139.84M -114.30M -54.05M
Other Cash from Investing Activities -7.12M -13.43M -2.03M -10.34M
Cash Provided by Financing Activities
Net Cash From Investing Activities -20.23M -119.34M -43.56M -29.52M
Issuance of Debt 0.00 0.00 120.00M 27.50M
Cash Used for Financing Activities
Issuance of Capital Stock 12.17M 118.88M 3.86M 63.73M
Repayment of Long-Term Debt 0.00 0.00 -27.50M -26.25M
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -1.47M 0.00 -7.19M -1.36M
Net Cash From Financing Activities 10.70M 118.88M 89.17M 63.61M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 19.46M 25.00M 2.39M -36.04M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

PCRX Pacira Pharmaceuticals Inc

Chart of PCRX

Analysts Ratings for PCRX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 7 6 6 7
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

PCRX Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs